Thelper

Description

Thelper develops antiviral antibody–drug conjugates that target a virally encoded biomarker abundantly expressed in aggressive, metastatic solid tumors, using next-generation linker technologies to improve tumor specificity and reduce toxicity in oncology applications.

Thelper is located in the Oslo ecosystem.

Related

• OncomatryxOncomatryx targets the tumor microenvironment with stroma-focused antibody-drug conjugates, applying this approach to metastatic solid…
• Rab DiagnosticsRab Diagnostics develops biomarker tools, assays and the RabCANCER platform to predict antibody–drug conjugate response for pharma…
• NETRIS PharmaNETRIS Pharma develops therapeutics that target Netrin-1 to overcome resistance to oncology treatments, producing monoclonal antibodies…
• TubulisTubulis generates antibody–drug conjugates and administers them with a proprietary platform that yields uniquely matched ADCs having…
• CytovationCytovation develops CyPep-1, a tumor membrane-targeted immunotherapy, using peptide engineering to activate immune recognition and tumor…
• ToxysToxys provides in vitro toxicity screening assays and services, including ToxTracker and ReproTracker, for mechanistic genotoxicity and…
• Numab TherapeuticsNumab Therapeutics engineers multispecific antibodies, combining antibody engineering and Swiss scientific expertise to build a proprietary…
• CimCureCimCure develops cancer vaccines using its proprietary iBoost conjugate technology to induce immune responses that target and destroy…
• EnzyTagEnzyTag develops peptiligase-based synthetic routes for manufacturing peptide new chemical entities, small proteins, and peptide…